Balchem vs Perimeter
BCPC and PRM side by side, both in chemicals and allied products. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BCPC and PRM compare
Balchem and Perimeter are about the same size, with market caps of $5.5B and $5.0B.
On earnings, Balchem is cheaper: it trades at 32.6× trailing earnings, against 170× for Perimeter.
Perimeter grew revenue faster over the last twelve months (30.7% versus 9.4% for Balchem).
Balchem keeps more of each dollar of sales as profit, with a net margin of 15.4% compared with 6.7% at Perimeter.
Balchem pays a dividend yielding 0.55%; Perimeter does not pay one.
Balchem scores higher on the StockData Score (19 against 7 for Perimeter), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BCPC | PRM |
|---|---|---|
| Size and price | ||
| Market cap | $5.5B | $5.0B |
| Share price | $173.30 | $30.67 |
| Change, 1 year | 11.6% | 19.7% |
| Change, 5 years | 3.5% | 138% |
| Beta (5Y) | 0.75 | 1.22 |
| Employees | 1,352 | 356 |
| StockData Score | ||
| Total score | 19 (better) | 7 |
| Valuation score | 2 (better) | 0 |
| Growth score | 4 (better) | 2 |
| Performance score | 5 (better) | 3 |
| Health score | 6 (better) | 2 |
| Dividend score | 2 (better) | 0 |
| Valuation | ||
| P/E | 32.6× (better) | 170× |
| P/S | 5.0× (better) | 6.0× |
| P/B | 4.2× | 3.8× (better) |
| EV/EBITDA | 19.5× (better) | 26.9× |
| P/FCF | – | 93.1× |
| PEG | 2.42 | – |
| FCF yield | – | 1.1% |
| Fair value | $151.95 | $9.21 |
| Margin of safety | −14.1% (better) | −233% |
| Growth | ||
| Revenue growth (TTM) | 9.4% | 30.7% (better) |
| Revenue growth, 5Y average | 8.1% | 14.0% (better) |
| Net income growth (TTM) | 14.5% (better) | −28.8% |
| EPS growth (TTM) | 16.2% (better) | −64.0% |
| EPS growth, 5Y average | 12.8% | – |
| Profitability | ||
| Gross margin | 36.5% | 54.5% (better) |
| Operating margin | 20.7% (better) | 14.5% |
| Net margin | 15.4% (better) | 6.7% |
| FCF margin | – | 6.5% |
| Return on equity | 13.0% (better) | 4.6% |
| Return on invested capital | 14.3% (better) | 6.3% |
| Financial health | ||
| Debt / equity | 0.00 | 0.91 (better) |
| Net debt / EBITDA | – | 4.82 |
| Interest coverage | – | 1.6× |
| Current ratio | 2.47 | 2.79 (better) |
| Altman Z-score | 11.06 (better) | 1.70 |
| Piotroski F-score | 9 (better) | 5 |
| Dividends and buybacks | ||
| Dividend yield | 0.55% | – |
| Payout ratio | 18.0% | – |
| Years of dividend growth | 3 | – |
| Buyback yield | 2.3% (better) | 0.00% |
| Shareholder yield | 2.8% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 91.3% | 85.6% |
| Held by insiders | 0.72% | 22.6% |
| Insider net buying, 12 months | −$2.2M (better) | −$435M |
| Superinvestors holding | – | 2 |
| Short interest, % of float | 1.6% | 5.2% |
Go deeper
- BCPC stock overview
- BCPC income statement
- BCPC valuation and score
- PRM stock overview
- PRM income statement
- PRM valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.